Chanussot C, Arenas R

Language: Spanish
References: 17
Page: 20-23
PDF size: 404.39 Kb.

ABSTRACT

Psoriasis is a chronic, multisystemic, inflammatory disease of immunogenic background, often associated to various comorbidities. The authors designed a descriptive, observational, retrospective study to determine the clinical and epidemiological features and comorbidities of patients with psoriasis at the Pemex General Hospital of Veracruz over the July 2006-September 2014 period. This paper describes the results.

REFERENCES

1. Arenas R. Dermatología. Atlas, diagnóstico y tratamiento. 5ª ed., México, McGraw Hill, 2013: 609-619.

2. Tavizón Ramos OE, Aguirre Gonzalez JD, Peralta Pedrero ML, Romero Alvarez J, Jurado Santa Cruz F. “Tratamiento farmacológico para pacientes adultos con psoriasis en placas”. Secretaría de Salud, México, 2013 [http://www.cenetec.salud.gob.mx]

3. Espinoza-Hernandez CJ, Lacy-Niebla RM, Soto-López ME, Kesch-Tronik NS, Vega-Memije ME. “Prevalencia del síndrome metabólico (SM) en pacientes con psoriasis”. Gac Med Mex 2014; 150: 311-316.

4. Ni C, Chiu M W. “Psoriasis and comorbidities: links and risks”. Clin Cosmetic Invest Dermatol 2014; 7: 119-132.

5. Aurangabadkar S. “Comorbidities in psoriasis”. Indian J Dermatol Venereol Leprol 2013; 79: 10-17.

6. Ponce-Rodríguez M, Mendoza R. “Características clínico-epidemiológicas de pacientes con psoriasis en un hospital nacional”. Dermatol Peru 2012; 22(3): 144-150.

7. Parisi R. Symmons D, Griffiths C. “Global epidemiology of Psoriasis: a systematic review of incidence and prevalence”. J Invest Dermatol 2013; 133: 377-385.

8. Prey S, Paul C, Bronsard V, Puzenat E. Gourraud PA, Aractingi S, et al. “Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature”. J Eur Acad Dermatol Venereol 2010; 24(Suppl.2): 31-35.

9. Rojas R, Castellanos H, Peñaranda E. “Prevalencia del síndrome metabólico, gravedad clínica y calidad de vida en pacientes con psoriasis del Hospital Universitario de la Samaritana”. Rev Asoc Colomb Dermatol 2013; 21(3): 220-225.

10. Engin B, Kutlubay Z, Yardimi G, Ambarcioglu P, Serdaroglu S, Tuzun Y. “Evaluation of Body Composition parameters in patients with psoriasis”. Int J Dermatol 2014; 53(12): 1468-1473.

11. Carrascosa JM, Rocamora V, Fernandez-Torers R, Jiménez-Puya R, Moreno JC, Coll-Pulgserver N, Fonseca E. “Obesidad y psoriasis: naturaleza inflamatoria de la obesidad, relación entre psoriasis y obesidad e implicaciones terapéuticas”. Actas Dermo Sifiliogr 2014; 105(1): 31-44.

12. Armstrong AW, Harskamp CT, Armstrong EJ. “Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies”. J Am Acad Dermatol. 2013; 68(4): 654-662.

13. Ford ES, Giles WH, Dietz WH. “Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination survey”. JAMA 2002; 287(3): 356-359.

14. Huskie J, Alendar F. “Tissue angiotensin-converting enzyme in patients with various clinical forms of psoriasis”. Bosn J Basic Med Sci 2007; 7(2): 103-106.

15. Jacobi A, Kupke C, Behzad M, Hertl M. “Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: a cross-sectional prospective study”. Int J Dermatol 2013; 46: 1081-1087.

16. Brauchli YB, Jick SS, Meier CR. “Psoriasis and the risk of incident diabetes mellitus: a population-based study”. Br J Dermatol. 2008; 159(6): 1331-1337.

17. Azfar RS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. “Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis”. Arch Dermatol 2012; 148(9): 995-1000.